The phase 1/2 TRIDENT-1 study investigated the efficacy and safety of the drug repotrectinib in patients with advanced solid tumors with a positive NTRK gene fusion[1]. Repotrectinib is a tyrosine kinase inhibitor that selectively blocks ROS1, TRKA−C and ALK proteins that cause uncontrolled growth of cancer cells[2]. The drug was safe and led to a permanent response of the tumors to the treatment[1]. In patients naïve to TRK inhibitors, 58% responded to repotrectinib, with responses lasting several months[2]. In patients already treated with TRK inhibitors, 50% of them responded, with a similar duration of response[2]. Repotrectinib has been approved by the FDA for the treatment of patients with NTRK-positive solid tumors and ROS1-positive non-small cell lung cancer[2]. The study continues to investigate the effectiveness of the drug in other groups of patients with advanced tumors[1].